Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen

Vaccine. 2010 Jul 12;28(31):4871-4874. doi: 10.1016/j.vaccine.2010.04.113. Epub 2010 May 16.

Abstract

APXIVA is an RTX toxin of Actinobacillus pleuropneumoniae that is a candidate antigen to differentiate infected from vaccinated animals (DIVA). Insertion of ISApl1 into the apxIVA gene is known to compromise an APXIVA-based DIVA approach, as is potentially a TGG to TGA mutation in the apxIVA gene. ISApl1 was found in 63/349 (18.1%) A. pleuropneumoniae isolates from England and Wales including serovars 2, 3, 6-8 and 12. No ISApl1 insertions into apxIVA were found. Only two serovar 3 isolates contained the TGG to TGA mutation. We conclude that an ApxIVA-based DIVA approach would potentially be viable in England and Wales.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actinobacillus Infections / immunology
  • Actinobacillus Infections / prevention & control
  • Actinobacillus pleuropneumoniae / genetics*
  • Actinobacillus pleuropneumoniae / immunology
  • Actinobacillus pleuropneumoniae / isolation & purification
  • Animals
  • Antigens, Bacterial / genetics
  • Antigens, Bacterial / immunology*
  • Bacterial Proteins / genetics
  • Bacterial Proteins / immunology*
  • DNA, Bacterial / genetics
  • England
  • Mutagenesis, Insertional
  • Mutation
  • Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • Wales

Substances

  • Antigens, Bacterial
  • ApxIVA protein, Actinobacillus pleuropneumoniae
  • Bacterial Proteins
  • DNA, Bacterial